6G4.2.5 (ATCC® HB-11722)

Organism: Mus musculus (B cell); Mus musculus (myeloma), mouse (B cell); mouse (myeloma)  /  Cell Type: hybridoma:lymphoblast B lymphocyte  / 

Permits and Restrictions

View Permits

Organism Mus musculus (B cell); Mus musculus (myeloma), mouse (B cell); mouse (myeloma)
Cell Type hybridoma:lymphoblast B lymphocyte
Product Format frozen
Morphology lymphoblast
Culture Properties suspension
Biosafety Level 1

Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country.

Strain

Strain: BALB/c (B cell); BALB/c (myeloma)

Storage Conditions liquid nitrogen vapor phase
Images
Derivation
An expression plasmid p6G425chim2 (ATCC 97055) was created to code for a chimeric murine-human Fab fragment of the monoclonal antibody. Cell lines producing the recombinant humanized antibody are available (ATCC CRL-12444 and ATCC CRL-12445)
Spleen cells were fused with P3X63Ag8U.1 mouse myeloma cells.
Genes Expressed
immunoglobulin; monoclonal antibody; against rabbit interleukin 8 (IL-8)
Cellular Products
immunoglobulin; monoclonal antibody; against rabbit interleukin 8 (IL-8)
Comments
An expression plasmid p6G425chim2 (ATCC 97055) was created to code for a chimeric murine-human Fab fragment of the monoclonal antibody. Cell lines producing the recombinant humanized antibody are available (ATCC CRL-12444 and ATCC CRL-12445)
Animals were immunized with rabbit interleukin 8 (IL-8).
Spleen cells were fused with P3X63Ag8U.1 mouse myeloma cells.
The antibody blocks IL-8 binding to rabbit neutrophil receptors.
Complete Growth Medium The base medium for this cell line is ATCC-formulated Dulbecco's Modified Eagle's Medium, Catalog No. 30-2002. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Subculturing
Protocol: Cultures can be maintained by addition of fresh medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 1 X 10(5) viable cells/ml. Do not allow the cell concentration to exceed 1 X 10 exp6 cells/ml.
Interval: Maintain cultures at a cell concentration between 1 X 10(5) and 1 X 10(6) cells/ml.
Medium Renewal: Evey 2 to 3 days
Cryopreservation
Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO
Storage temperature: liquid nitrogen vapor phase
Culture Conditions
Atmosphere: air, 95%; carbon dioxide (CO2), 5%
Temperature: 37.0°C
Isotype IgG2a kappa , IgG2a
Name of Depositor Genentech, Inc.
U.S. Patent Number
References

Fong S, et al. Anti-IL-8 antibody fragments. US Patent 5,677,426 dated Oct 14 1997

Hsei V, et al. Methods of treating inflammatory diseases with anti-IL-8 antibody fragment-polymer conjugates. US Patent 6,468,532 dated Oct 22 2002

Hsei V, et al. Methods of treating inflammatory disease with anti-IL-8 antibody fragment-polymer conjugates. US Patent 6,458,355 dated Oct 1 2002

Gonzalez TN, et al. Humanized anti-IL-8 monoclonal antibodies. US Patent 6,133,426 dated Oct 17 2000

Gonzalez TN, et al. Humanized anti-IL-8 monoclonal antibodies. US Patent 6,117,980 dated Sep 12 2000

Gonzalez TN, et al. Nucleic acids encoding humanized anti-IL-8 monoclonal antibodies. US Patent 6,025,158 dated Feb 15 2000

Notice: Necessary PermitsPermits

These permits may be required for shipping this product:

  • Customers located in the state of Hawaii will need to contact the Hawaii Department of Agriculture to determine if an Import Permit is required. A copy of the permit or documentation that a permit is not required must be sent to ATCC in advance of shipment.
Basic Documentation
Other Documentation
References

Fong S, et al. Anti-IL-8 antibody fragments. US Patent 5,677,426 dated Oct 14 1997

Hsei V, et al. Methods of treating inflammatory diseases with anti-IL-8 antibody fragment-polymer conjugates. US Patent 6,468,532 dated Oct 22 2002

Hsei V, et al. Methods of treating inflammatory disease with anti-IL-8 antibody fragment-polymer conjugates. US Patent 6,458,355 dated Oct 1 2002

Gonzalez TN, et al. Humanized anti-IL-8 monoclonal antibodies. US Patent 6,133,426 dated Oct 17 2000

Gonzalez TN, et al. Humanized anti-IL-8 monoclonal antibodies. US Patent 6,117,980 dated Sep 12 2000

Gonzalez TN, et al. Nucleic acids encoding humanized anti-IL-8 monoclonal antibodies. US Patent 6,025,158 dated Feb 15 2000